0 CHECKOUT

Gene Therapy-Industry Impact

  • ID: 435355
  • December 2006
  • 125 Pages
  • Frost & Sullivan

This Frost & Sullivan research service titled Advances in Gene Therapy provides an overview of the current developments and advanced technologies in gene therapy, along with a complete analysis of the key market drivers, restraints, applications, and trends that are impacting this field. In this study, Frost & Sullivan's expert analysts thoroughly examine gene-delivery vehicles and technologies, vector design, DNA vaccine design, and the clinical status of product candidates.

Technologies
The following technologies are covered in this research:

-Gene-delivery vehicles and technologies
-Vector design
-DNA vaccine design
-Clinical status of product candidates

Technology Sectors
Expert analysts thoroughly examine the following technology sectors in this research:

-Clinical therapeutics
-Biotechnology
-Biopharmaceuticals

Technology Overview
Growing Popularity of DNA Vaccines Boost Advances in Gene Therapy

Gene therapy is likely to be practiced in clinics in the near future, with a number of candidates now in phase II/III trials, showing promising results. The first gene therapy products, already in late-stage clinical READ MORE >

Note: Product cover images may vary from those shown

-1. Executive Summary
--1. Scope and Methodology
---1. Scope
---2. Methodology
--2. Introduction and History of Gene Therapy
---1. Introduction
---2. History of Gene Therapy

-2. Technology and Applications Viewpoint
--1. Technology Primer
---1. Gene delivery--Vectors; Vehicles; Chemical and Physical Methods
---2. DNA Vaccines
---3. Additional Approaches
--2. Applications Analysis and Trends
---1. Targets Closest to Market
---2. Ocular Disorders--Macular Degeneration And Retinopathy
---3. Diabetes
---4. Cystic Fibrosis
---5. Rheumatoid Arthritis
---6. Types of Disorders
---7. Coronary Artery Disease
---8. Peripheral Artery Disease
---9. Cancer
---10. DNA Vaccines
--3. Assessment of Stakeholder Innovation and Technology Transfer Opportunities--Influential Market Factors
---1. Mergers and Acquisitions Analysis
---2. Regulatory and Political Factors; Industry Trends

-3. Technology Adoption Factor Analysis
--1. Regulatory Hurdles
---1. Safety Issues and Regulatory Barriers
---2. Clinical Trials
--2. Technology or Product Development Restraints and Competing Technologies
---1. Technical Barriers
---2. Lack of Investor Confidence
---3. Gene Patents; Cost and Other Barriers
---4. Stem Cells and Other Cellular Therapies
--3. Analysis of Drivers
---1. Analysis of Funding Sources
---2. Features and Benefits of Gene Therapy
---3. Adoption Drivers for Gene Therapy

-4. Assessment of Innovations and Opportunities
--1. Innovative Developments in North America--Gene Therapy
---1. Targeting Cancer Cells with Antibody/Gene/Liposome Nanocomplex
---2. Polymer Delivers IL-12 Gene Therapy for Cancer
---3. Gene Therapy Promotes Blood Vessel Growth in Peripheral Artery Disease
---4. Lentiviral Vectors in Development
---5. p53 Gene Therapy for Esophageal Cancer
---6. Collagen Used as Target for Cancer Gene Therapy
---7. Nanotechnology Gene Therapy for Prostate Cancer
---8. Microbubbles Release Therapeutic Genes with Ultrasound
---9. Autoantigen-Plasmid Drug Promising against MS
---10. Zinc-Finger Protein Agent for Diabetic Neuropathy
---11. Gene Therapy for Epilepsy and Parkinson’s Disease
---12. Gene Therapy for Osteoarthritis
---13. Naked DNA for Cancer Gene Therapy
---14. Bare Metal Stents Deliver Gene Therapy to Treat Heart Disease
---15. Gene Immunotherapy--T Cells Transformed into Tumor Fighting Cells
---16. Emphysema Gene Therapy
---17. Hedgehog Agonist Gene for Diabetic Wound Healing
---18. Nanoparticles for DNA Delivery
---19. FGF Gene Therapy for Myocardial Ischemia
---20. Neurturin Gene Therapy for Parkinson’s Disease in Phase II Trials
---21. Light-Activated Gene Therapy Targets Knee Injuries; Other Tissue Repair
---22. New Lipid Molecule Holds Promise for Gene Therapy
---23. Additional Companies
--2. Innovative Developments in North America--DNA Vaccines
---1. Flu DNA Vaccine Candidate Delivered via Needle-Free Injection
---2. DOGS Cation Compound Enhances DNA Vaccines
---3. Short ISS DNA Sequences Stimulate Immune Responses
---4. Cell-Free Production of DNA for Flu Vaccine
---5. DNA Bird Flu Vaccine Protects Lab Animals
---6. DNA West Nile Vaccine Triggers Immune Response in Human Subjects
---7. HIV Vaccines
---8. Leukemia Vaccine Uses Tumor Cells Transfected with GM-CSF Gene
---9. Adenoviral TB Vaccine
---10. Clinical Trial for Ebola Vaccine
--3. Innovative Developments in Europe--Gene Therapy
---1. Gene Therapy for Critical Limb Ischemia
---2. Interferon Vector for Cutaneous Lymphoma
---3. Belgian and Dutch Companies Seek Spinal Gene Therapies
---4. Gene Therapy Appears to Cure Myeloid Disease in Human Subjects
---5. Additional Companies
--4. Innovative Developments in Europe--DNA Vaccines
---1. Adoptive Cell Therapy for Melanoma Vaccine
---2. E6 and E7 Genes in HPV Vaccine Clinical Trials
---3. Vaccine for Kidney Cancer
---4. HIV Vaccines
--5. Innovative Developments in the Asia Pacific Region
---1. Gendicine p53 Gene Therapy Follow-up
---2. Gene Therapy Successfully Treats Hemophilia
---3. Hepatocyte Growth Factor for Liver and Circulatory Disorders
---4. DNA Ointment for Atopic Dermatitis

-5. Patents and Database of Key Industry Participants
--1. Patents
---1. Key Patents (2005)
---2. Key Patents (2006)
--2. Database of Key Industry Participants
---1. Corporate Sector
---2. Laboratories and Universities

-6. Decision Support Database
--1. Database Tables
---1. Total Healthcare Expenditure--World (2002 to 2012)
---2. Government Healthcare Expenditure--World (2002 to 2012)
---3. Private Healthcare Expenditure--World (2002 to 2012)
2012)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: A copy of the report will be emailed to you and a printed copy will be shipped to you. The Electronic copy is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A copy of the report will be emailed to you and a printed copy will be shipped to you. The Electronic copy is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Promega Corporation
  • Roche Diagnostics Ltd.
  • KeyGene N.V.
  • Celera Corporation
  • Qiagen N.V.
  • University of California at Santa Barbara